HK1017905A1 - Induction of T cell tolerance using a soluble molecule that can simultaneously block two costimulatory pathways. - Google Patents

Induction of T cell tolerance using a soluble molecule that can simultaneously block two costimulatory pathways.

Info

Publication number
HK1017905A1
HK1017905A1 HK99102918A HK99102918A HK1017905A1 HK 1017905 A1 HK1017905 A1 HK 1017905A1 HK 99102918 A HK99102918 A HK 99102918A HK 99102918 A HK99102918 A HK 99102918A HK 1017905 A1 HK1017905 A1 HK 1017905A1
Authority
HK
Hong Kong
Prior art keywords
induction
human
cell tolerance
binding
ligand
Prior art date
Application number
HK99102918A
Other languages
English (en)
Inventor
Mark De Boer
Original Assignee
Pangenetics Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pangenetics Bv filed Critical Pangenetics Bv
Publication of HK1017905A1 publication Critical patent/HK1017905A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70521—CD28, CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/626—Diabody or triabody
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/026—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a baculovirus
HK99102918A 1996-07-23 1999-07-08 Induction of T cell tolerance using a soluble molecule that can simultaneously block two costimulatory pathways. HK1017905A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US2207096P 1996-07-23 1996-07-23
PCT/NL1997/000438 WO1998003670A1 (fr) 1996-07-23 1997-07-23 Induction de la tolerance aux lymphocytes t au moyen d'une molecule soluble pouvant bloquer simultanement deux mecanismes d'action costimulants

Publications (1)

Publication Number Publication Date
HK1017905A1 true HK1017905A1 (en) 1999-12-03

Family

ID=21807674

Family Applications (1)

Application Number Title Priority Date Filing Date
HK99102918A HK1017905A1 (en) 1996-07-23 1999-07-08 Induction of T cell tolerance using a soluble molecule that can simultaneously block two costimulatory pathways.

Country Status (8)

Country Link
US (1) US20020150559A1 (fr)
EP (1) EP0922111B1 (fr)
JP (1) JP4219985B2 (fr)
AT (1) ATE283925T1 (fr)
CA (1) CA2260752A1 (fr)
DE (1) DE69731836T2 (fr)
HK (1) HK1017905A1 (fr)
WO (1) WO1998003670A1 (fr)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU8800598A (en) * 1997-06-20 1999-01-04 Innogenetics N.V. B7-binding molecules for treating immune diseases
JP2002502824A (ja) * 1998-02-04 2002-01-29 ザ・ジェネラル・ホスピタル・コーポレイション 同種移植における補刺激遮断および混合キメラ現象
FR2789089A1 (fr) * 1999-02-02 2000-08-04 Pf Medicament Lymphocytes t humains effecteurs exprimant la molecule cd86 et possedant des proprietes immunodulatrices, costimulatrices et cytotoxiques, leurs procedes d'obtention et leurs applications
JP2003510371A (ja) * 1999-10-04 2003-03-18 カイロン コーポレイション 乾癬を処置するためのｃｄ４０アンタゴニスト
EP1839674A1 (fr) * 1999-10-04 2007-10-03 Novartis Vaccines and Diagnostics, Inc. Antagoniste CD40 pour le traitement du psoriasis
AU2001259106A1 (en) * 2000-04-19 2002-02-18 Tanox, Inc. CD40 antagonists for use in treating psoriasis and other inflammatory skin conditions
US20030059888A1 (en) * 2001-08-22 2003-03-27 Shengfeng Li Compositions and methods for generating antigen-binding units
EP1599502A1 (fr) * 2003-02-27 2005-11-30 TheraVision GmbH Molecule se liant a cd80 et cd86
US20070009517A1 (en) * 2003-08-25 2007-01-11 Mark De Boer Method of inducing immune tolerance
EP1854810A1 (fr) 2006-05-09 2007-11-14 PanGenetics B.V. Anticorps monoclonal anti CD40 humain déimmunisé et antagoniste dérivé de l'anticorps ch5D12
EP2535349A1 (fr) 2007-09-26 2012-12-19 UCB Pharma S.A. Fusions d'anticorps à double spécificité
DK2334705T3 (en) * 2008-09-26 2017-03-27 Ucb Biopharma Sprl BIOLOGICAL PRODUCTS
WO2010040105A2 (fr) * 2008-10-02 2010-04-08 Trubion Pharmaceuticals, Inc. Protéines de liaison multicibles antagonistes de cd86
EP2356150A2 (fr) * 2008-10-10 2011-08-17 Emergent Product Development Seattle, LLC Immunothérapie impliquant le complexe tcr
CA2870545A1 (fr) 2012-04-20 2013-10-24 Emergent Product Development Seattle, Llc Polypeptides se liant a cd3
WO2014116846A2 (fr) * 2013-01-23 2014-07-31 Abbvie, Inc. Procédés et compositions pour moduler une réponse immunitaire
EP2883883A1 (fr) 2013-12-16 2015-06-17 Cardio3 Biosciences S.A. Cibles thérapeutiques et agents utiles dans le traitement des lésions ischémiques de reperfusion
EP2930188A1 (fr) * 2014-04-13 2015-10-14 Affimed Therapeutics AG Molécule de liaison à l'antigène trifonctionnel
EP3148580B1 (fr) 2014-05-29 2021-01-20 MacroGenics, Inc. Molécules de liaison tri-spécifiques se liant spécifiquement à de multiples antigènes tumoraux, et méthodes d'utilisation de celles-ci
WO2017053469A2 (fr) 2015-09-21 2017-03-30 Aptevo Research And Development Llc Polypeptides de liaison à cd3
RU2731202C2 (ru) 2015-10-08 2020-08-31 Макродженикс, Инк. Комбинированная терапия для лечения рака
CN108264561B (zh) * 2016-12-30 2021-09-10 惠和生物技术(上海)有限公司 一种结合cd19、cd3和t细胞负共刺激分子的三功能分子及其应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) * 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
JPS5896026A (ja) * 1981-10-30 1983-06-07 Nippon Chemiphar Co Ltd 新規ウロキナ−ゼ誘導体およびその製造法ならびにそれを含有する血栓溶解剤
US4609546A (en) * 1982-06-24 1986-09-02 Japan Chemical Research Co., Ltd. Long-acting composition
US4766106A (en) * 1985-06-26 1988-08-23 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
US5225539A (en) * 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5869620A (en) * 1986-09-02 1999-02-09 Enzon, Inc. Multivalent antigen-binding proteins
US4946778A (en) * 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
DE69334255D1 (de) * 1992-02-06 2009-02-12 Novartis Vaccines & Diagnostic Marker für Krebs und biosynthetisches Bindeprotein dafür
US5397703A (en) * 1992-07-09 1995-03-14 Cetus Oncology Corporation Method for generation of antibodies to cell surface molecules
CA2150262C (fr) * 1992-12-04 2008-07-08 Kaspar-Philipp Holliger Proteines fixatrices multivalentes et multispecifiques, fabrication et utilisation
GB9412166D0 (en) * 1993-09-22 1994-08-10 Medical Res Council Retargetting antibodies
US6051228A (en) * 1998-02-19 2000-04-18 Bristol-Myers Squibb Co. Antibodies against human CD40

Also Published As

Publication number Publication date
ATE283925T1 (de) 2004-12-15
JP2000515374A (ja) 2000-11-21
CA2260752A1 (fr) 1998-01-29
EP0922111B1 (fr) 2004-12-01
EP0922111A1 (fr) 1999-06-16
DE69731836D1 (de) 2005-01-05
DE69731836T2 (de) 2005-12-01
WO1998003670A1 (fr) 1998-01-29
JP4219985B2 (ja) 2009-02-04
US20020150559A1 (en) 2002-10-17

Similar Documents

Publication Publication Date Title
HK1017905A1 (en) Induction of T cell tolerance using a soluble molecule that can simultaneously block two costimulatory pathways.
MX9602879A (es) Moleculas mutantes de ctla4 y usos de las mismas.
AU4612093A (en) Soluble ligands for CD40
AU2821195A (en) Cross-reacting monoclonal antibodies specific for e-selectin and p-selectin
NZ333607A (en) Method of stimulating the immune system by transfecting dendritic cells
AU3889399A (en) Vaccine delivery system
AU7856700A (en) Composition and method of cancer antigen immunotherapy
PL331091A1 (en) Therapeutic multispecific compounds encompassing antibodies against the fcalpha receptor
CA2290485A1 (fr) Procede de production de proteines non immunogenes
EP0920623A4 (fr) Therapie par capture de neutrons de bore dans laquelle des procedes de pre-ciblage sont utilises
EP0614355A4 (en) Antitumor vaccines.
GB2355983B (en) Method for producing or enhancing a T-cell response against a target cell using a complex comprising an HLA class 1 molecule and an attaching means
WO2000067788A3 (fr) Emploi de molecules de co-stimulation solubles favorisant les reponses immunitaires
AU2002354806A1 (en) Parathyroid hormone antibodies and related methods
NZ500151A (en) A general method for attaching DNA molecule comprising non-antibody target molecule (eg. CTLA-4 or L-selectin), antigen or epitope sequence, and optionally a polypeptide sequence
UY26266A1 (es) Antigeno asociado con tumores (r11) ley 17164
WO1999065517A3 (fr) Compositions therapeutiques produisant une reponse immunitaire par renouvellement des antigenes
EP0202642A3 (fr) Procédé pour l'immunisation in vitro de splénocytes humains contre des antigènes associés aux tumeurs
NZ331398A (en) Tumor rejection antigens presented by hla-b44 molecules, and uses thereof
HK1057233A1 (en) Hybrid cells obtainable from antigen presenting cells
WO1997013858A3 (fr) Homologues de mage-3 du babouin, adn codant pour ceux-ci et technique d'utilisation associee
WO2005061537A3 (fr) Antigenes associes aux tumeurs et leur utilisation
WO2002036146A3 (fr) Therapie du cancer
HK1016482A1 (en) Tumor rejection antigens presented by hla-b44 molecules, and uses thereof.
WO1997038711A3 (fr) Vaccin derive de lymphocytes et recepteur de surface cellulaire cd28_____________________________________________________________

Legal Events

Date Code Title Description
CHPA Change of a particular in the register (except of change of ownership)
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20100723